| Metric | Q2 2026 | Q2 2025 |
|---|---|---|
| Revenue | 2.3 | 1.8 |
| Gross profit | 0.2 | -0.3 |
| Profit before tax | -8.2 | -8.3 |
| Net income | -7.8 | -7.9 |
| EPS (diluted, $ a share) | $-3.76 | $-24.98 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +27.8% |
|---|---|
| Gross margin | 8.5% |
| Operating margin | -257.1% |
10-Q filed with the SEC, NASDAQ: XAIR. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Beyond Air, Inc.: key numbers
- Share price
- $2.02Close, Nov 16
- Market cap
- $3.37M
- Shares outstanding
- 1.67MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Beyond Air, Inc.
All →Beyond Air Financial Results
Beyond Air reported record quarterly revenue of $2.3 million for the period ended September 30, 2026, representing 28% year-over-year growth. The company reaffirmed its revenue guidance of $8 million for CY2026 and $16-$18 million for CY2027 while awaiting FDA approval for its second-generation LungFit PH system.
- Term
- Q2 2027
“Building on the commercial momentum we are generating with our first-generation LungFit PH system, we believe our second-generation system has the potential to substantially expand our market opportunity and accelerate growth, pending FDA approval.”
Robert Goodman, Chief Executive Officer of Beyond Air
“We remain encouraged by our active and productive discussions with the FDA and the progress we are making toward completing the remaining steps in the review process for the second-generation LungFit PH system.”
Robert Goodman, Chief Executive Officer of Beyond Air
Beyond Air Business Update
Beyond Air preannounced preliminary unaudited revenue of $2.3 million for the quarter ended September 30, 2026, representing 30% sequential growth. The company also reaffirmed its full-year revenue guidance for 2026 and 2027 while noting its second-generation LungFit PH system remains under FDA review.
Beyond Air Insider Yi-Chien Lin Buys $43.1K of Stock
Yi-Chien Lin bought 15,393 shares of Beyond Air, Inc. at $2.80 a share, worth $43.1K in total on Oct 1, 2026. Shares held after the trade: 145,393 (+11.8%).
- Value
- $43.1K
- Shares
- 15,393
- Price
- $2.80
- Holding change
- +11.8%
- Trade date
- Oct 1, 2026